Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardial Infarction | 19 | 2017 | 424 | 2.950 |
Why?
|
Coronary Artery Bypass | 12 | 2017 | 100 | 2.560 |
Why?
|
Heart Valve Prosthesis Implantation | 8 | 2018 | 41 | 2.420 |
Why?
|
Heart Valve Prosthesis | 5 | 2018 | 53 | 2.270 |
Why?
|
Aortic Valve Stenosis | 5 | 2018 | 29 | 2.160 |
Why?
|
Aortic Valve | 4 | 2018 | 48 | 1.940 |
Why?
|
Bioprosthesis | 4 | 2018 | 55 | 1.840 |
Why?
|
Aortic Valve Insufficiency | 3 | 2018 | 24 | 1.370 |
Why?
|
Coronary Artery Disease | 12 | 2017 | 377 | 1.370 |
Why?
|
Thrombolytic Therapy | 6 | 2013 | 59 | 1.280 |
Why?
|
Vascular Surgical Procedures | 3 | 2017 | 91 | 1.260 |
Why?
|
Stents | 7 | 2018 | 171 | 1.140 |
Why?
|
Bone Marrow Transplantation | 12 | 2017 | 65 | 1.130 |
Why?
|
Treatment Outcome | 27 | 2018 | 3128 | 1.120 |
Why?
|
Myocardial Reperfusion | 4 | 2012 | 10 | 1.100 |
Why?
|
Ventricular Dysfunction, Left | 10 | 2017 | 137 | 1.050 |
Why?
|
Humans | 72 | 2020 | 29614 | 0.960 |
Why?
|
Time Factors | 17 | 2020 | 2014 | 0.950 |
Why?
|
Risk Assessment | 7 | 2020 | 1329 | 0.930 |
Why?
|
Heart-Assist Devices | 5 | 2011 | 19 | 0.870 |
Why?
|
Coronary Disease | 4 | 2013 | 202 | 0.850 |
Why?
|
Heart Transplantation | 4 | 2011 | 26 | 0.830 |
Why?
|
Platelet Aggregation Inhibitors | 7 | 2017 | 85 | 0.800 |
Why?
|
Electrocardiography | 8 | 2015 | 571 | 0.790 |
Why?
|
Prosthesis Failure | 2 | 2018 | 43 | 0.770 |
Why?
|
Disease Management | 5 | 2015 | 114 | 0.750 |
Why?
|
Catheterization, Peripheral | 2 | 2017 | 25 | 0.700 |
Why?
|
Thrombosis | 2 | 2017 | 60 | 0.700 |
Why?
|
Aged | 25 | 2019 | 9617 | 0.680 |
Why?
|
Shock, Cardiogenic | 2 | 2011 | 7 | 0.680 |
Why?
|
Coronary Angiography | 6 | 2016 | 139 | 0.670 |
Why?
|
Coronavirus Infections | 1 | 2020 | 72 | 0.660 |
Why?
|
Retrospective Studies | 14 | 2019 | 3145 | 0.660 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 77 | 0.660 |
Why?
|
Female | 34 | 2019 | 18414 | 0.630 |
Why?
|
Acute Coronary Syndrome | 1 | 2020 | 177 | 0.630 |
Why?
|
Risk Factors | 11 | 2020 | 3612 | 0.620 |
Why?
|
Tricuspid Valve | 1 | 2017 | 5 | 0.620 |
Why?
|
Fibrinolytic Agents | 3 | 2013 | 70 | 0.610 |
Why?
|
Foramen Ovale, Patent | 1 | 2017 | 7 | 0.610 |
Why?
|
Femoral Artery | 1 | 2017 | 44 | 0.600 |
Why?
|
Respiratory Insufficiency | 1 | 2017 | 61 | 0.570 |
Why?
|
Mitral Valve Stenosis | 1 | 2016 | 8 | 0.570 |
Why?
|
Cardiology | 7 | 2016 | 83 | 0.570 |
Why?
|
Iliac Artery | 2 | 2014 | 46 | 0.570 |
Why?
|
Echocardiography | 2 | 2016 | 141 | 0.570 |
Why?
|
Middle Aged | 27 | 2019 | 10954 | 0.560 |
Why?
|
Practice Guidelines as Topic | 4 | 2015 | 376 | 0.550 |
Why?
|
Male | 32 | 2019 | 18037 | 0.550 |
Why?
|
Balloon Occlusion | 3 | 2014 | 29 | 0.510 |
Why?
|
Aged, 80 and over | 9 | 2019 | 3771 | 0.510 |
Why?
|
Prosthesis Design | 4 | 2018 | 87 | 0.510 |
Why?
|
Heart Valve Prolapse | 1 | 2014 | 1 | 0.510 |
Why?
|
Evidence-Based Medicine | 8 | 2015 | 209 | 0.470 |
Why?
|
Myocardial Ischemia | 6 | 2015 | 85 | 0.460 |
Why?
|
Ticlopidine | 1 | 2013 | 17 | 0.450 |
Why?
|
Steroids | 1 | 2013 | 36 | 0.440 |
Why?
|
Coronary Vessels | 3 | 2016 | 151 | 0.440 |
Why?
|
Aspirin | 1 | 2013 | 66 | 0.430 |
Why?
|
Radial Artery | 1 | 2012 | 15 | 0.430 |
Why?
|
Specialization | 1 | 2012 | 30 | 0.430 |
Why?
|
Cardiovascular Diseases | 2 | 2012 | 1058 | 0.420 |
Why?
|
Cardiac Surgical Procedures | 2 | 2011 | 71 | 0.400 |
Why?
|
Drug-Eluting Stents | 3 | 2017 | 16 | 0.400 |
Why?
|
American Heart Association | 5 | 2016 | 84 | 0.390 |
Why?
|
Advanced Cardiac Life Support | 1 | 2011 | 4 | 0.390 |
Why?
|
Life Support Care | 1 | 2011 | 15 | 0.390 |
Why?
|
Heart Arrest | 1 | 2011 | 39 | 0.380 |
Why?
|
Life Support Systems | 1 | 2010 | 4 | 0.380 |
Why?
|
Adult | 17 | 2019 | 8535 | 0.380 |
Why?
|
Coronary Circulation | 2 | 2012 | 30 | 0.370 |
Why?
|
Bone Marrow Cells | 4 | 2016 | 115 | 0.370 |
Why?
|
Hemorrhage | 4 | 2017 | 94 | 0.350 |
Why?
|
Ischemic Preconditioning, Myocardial | 1 | 2009 | 3 | 0.350 |
Why?
|
Asthma | 1 | 2013 | 397 | 0.350 |
Why?
|
Hemodynamics | 4 | 2018 | 148 | 0.350 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2009 | 19 | 0.350 |
Why?
|
Patient Selection | 5 | 2013 | 257 | 0.340 |
Why?
|
Graft Rejection | 3 | 2011 | 149 | 0.330 |
Why?
|
Heart Failure | 5 | 2018 | 576 | 0.330 |
Why?
|
Operating Rooms | 1 | 2009 | 32 | 0.330 |
Why?
|
Hypertension, Pulmonary | 3 | 2014 | 23 | 0.320 |
Why?
|
Time and Motion Studies | 1 | 2008 | 6 | 0.320 |
Why?
|
Total Quality Management | 1 | 2008 | 19 | 0.310 |
Why?
|
Hospitals, University | 1 | 2008 | 23 | 0.310 |
Why?
|
Coronary Stenosis | 1 | 2007 | 28 | 0.300 |
Why?
|
Recovery of Function | 3 | 2018 | 190 | 0.300 |
Why?
|
Sirolimus | 1 | 2007 | 35 | 0.300 |
Why?
|
Internal Mammary-Coronary Artery Anastomosis | 1 | 2006 | 1 | 0.290 |
Why?
|
Coronary Artery Bypass, Off-Pump | 1 | 2006 | 7 | 0.290 |
Why?
|
Drug Delivery Systems | 1 | 2007 | 94 | 0.280 |
Why?
|
Diagnostic Techniques, Cardiovascular | 4 | 2012 | 10 | 0.280 |
Why?
|
Medication Therapy Management | 4 | 2012 | 12 | 0.270 |
Why?
|
Ventricular Function, Left | 6 | 2016 | 198 | 0.270 |
Why?
|
Coronary Vasospasm | 1 | 2005 | 4 | 0.270 |
Why?
|
United States | 8 | 2016 | 3695 | 0.270 |
Why?
|
Vasoconstriction | 1 | 2005 | 40 | 0.260 |
Why?
|
Pulmonary Wedge Pressure | 2 | 2014 | 7 | 0.240 |
Why?
|
Severity of Illness Index | 3 | 2018 | 864 | 0.240 |
Why?
|
Clinical Protocols | 3 | 2012 | 95 | 0.240 |
Why?
|
Thrombectomy | 2 | 2015 | 58 | 0.230 |
Why?
|
Emergency Medical Services | 4 | 2012 | 158 | 0.230 |
Why?
|
Combined Modality Therapy | 6 | 2013 | 525 | 0.230 |
Why?
|
Saphenous Vein | 2 | 2017 | 20 | 0.220 |
Why?
|
Radiography | 2 | 2014 | 355 | 0.220 |
Why?
|
Cohort Studies | 6 | 2016 | 1708 | 0.220 |
Why?
|
Myocardium | 2 | 2010 | 170 | 0.220 |
Why?
|
Chemokines, CXC | 1 | 2002 | 9 | 0.220 |
Why?
|
Receptors, Chemokine | 1 | 2002 | 9 | 0.210 |
Why?
|
Neovascularization, Pathologic | 1 | 2003 | 81 | 0.210 |
Why?
|
Interferon-gamma | 1 | 2002 | 51 | 0.210 |
Why?
|
Stroke Volume | 6 | 2017 | 282 | 0.210 |
Why?
|
Vascular Diseases | 1 | 2002 | 62 | 0.200 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2002 | 100 | 0.200 |
Why?
|
Double-Blind Method | 8 | 2017 | 507 | 0.200 |
Why?
|
Follow-Up Studies | 6 | 2017 | 2124 | 0.190 |
Why?
|
Echocardiography, Transesophageal | 3 | 2011 | 40 | 0.190 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2017 | 471 | 0.190 |
Why?
|
Equipment Design | 3 | 2011 | 167 | 0.180 |
Why?
|
Punctures | 2 | 2017 | 32 | 0.180 |
Why?
|
Leukocytes, Mononuclear | 2 | 2010 | 50 | 0.180 |
Why?
|
Stem Cell Transplantation | 2 | 2013 | 203 | 0.170 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 22 | 0.170 |
Why?
|
Genetic Predisposition to Disease | 2 | 2014 | 840 | 0.170 |
Why?
|
Academic Medical Centers | 1 | 2020 | 150 | 0.170 |
Why?
|
Spinal Fusion | 1 | 2019 | 42 | 0.170 |
Why?
|
Decompression, Surgical | 1 | 2019 | 53 | 0.160 |
Why?
|
Lung Injury | 1 | 2019 | 64 | 0.160 |
Why?
|
Surgical Wound Infection | 1 | 2019 | 74 | 0.160 |
Why?
|
Neurosurgical Procedures | 1 | 2019 | 98 | 0.160 |
Why?
|
Lumbar Vertebrae | 1 | 2019 | 99 | 0.160 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 156 | 0.160 |
Why?
|
Antigens, CD34 | 2 | 2016 | 54 | 0.160 |
Why?
|
Endothelial Cells | 1 | 2019 | 180 | 0.150 |
Why?
|
Septal Occluder Device | 1 | 2017 | 4 | 0.150 |
Why?
|
Graft Occlusion, Vascular | 1 | 2017 | 22 | 0.150 |
Why?
|
Regeneration | 1 | 2019 | 168 | 0.150 |
Why?
|
Colony-Forming Units Assay | 2 | 2014 | 17 | 0.150 |
Why?
|
Lung | 1 | 2019 | 237 | 0.150 |
Why?
|
Incidence | 1 | 2020 | 1128 | 0.140 |
Why?
|
Echocardiography, Doppler | 1 | 2016 | 39 | 0.140 |
Why?
|
C-Reactive Protein | 2 | 2016 | 235 | 0.140 |
Why?
|
Young Adult | 3 | 2019 | 2432 | 0.140 |
Why?
|
Patient Discharge | 1 | 2017 | 171 | 0.140 |
Why?
|
Length of Stay | 1 | 2017 | 296 | 0.140 |
Why?
|
Databases, Factual | 1 | 2017 | 333 | 0.140 |
Why?
|
North Carolina | 1 | 2020 | 1430 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2015 | 37 | 0.130 |
Why?
|
Exercise Tolerance | 1 | 2016 | 110 | 0.130 |
Why?
|
Stem Cells | 2 | 2015 | 295 | 0.130 |
Why?
|
Societies, Medical | 1 | 2016 | 150 | 0.130 |
Why?
|
Vascular Resistance | 1 | 2014 | 28 | 0.120 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 49 | 0.120 |
Why?
|
Device Removal | 1 | 2014 | 31 | 0.120 |
Why?
|
Genomics | 2 | 2012 | 82 | 0.120 |
Why?
|
Cell Separation | 2 | 2012 | 87 | 0.120 |
Why?
|
Vasodilation | 1 | 2014 | 87 | 0.120 |
Why?
|
Transcription Factor RelA | 1 | 2014 | 23 | 0.120 |
Why?
|
Ependymoma | 1 | 2014 | 5 | 0.120 |
Why?
|
Fluid Therapy | 1 | 2013 | 27 | 0.120 |
Why?
|
NF-kappa B | 1 | 2014 | 77 | 0.120 |
Why?
|
Asian Continental Ancestry Group | 1 | 2014 | 110 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2014 | 58 | 0.120 |
Why?
|
Terminology as Topic | 1 | 2013 | 63 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2013 | 42 | 0.110 |
Why?
|
Dyslipidemias | 1 | 2014 | 54 | 0.110 |
Why?
|
Tissue Plasminogen Activator | 1 | 2013 | 40 | 0.110 |
Why?
|
Signal Transduction | 2 | 2014 | 674 | 0.110 |
Why?
|
Proteins | 1 | 2014 | 141 | 0.110 |
Why?
|
Fluoroscopy | 1 | 2012 | 39 | 0.110 |
Why?
|
Drug Administration Schedule | 1 | 2013 | 247 | 0.110 |
Why?
|
Mutation | 2 | 2012 | 475 | 0.110 |
Why?
|
Critical Illness | 1 | 2013 | 88 | 0.110 |
Why?
|
Regenerative Medicine | 2 | 2012 | 192 | 0.100 |
Why?
|
Retinoblastoma | 1 | 2012 | 10 | 0.100 |
Why?
|
Neuregulin-1 | 1 | 2011 | 1 | 0.100 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 9 | 0.100 |
Why?
|
Tennessee | 2 | 2011 | 97 | 0.100 |
Why?
|
Tissue and Organ Harvesting | 1 | 2012 | 35 | 0.100 |
Why?
|
Hemostatic Techniques | 1 | 2011 | 7 | 0.100 |
Why?
|
Femoral Vein | 1 | 2011 | 10 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 80 | 0.100 |
Why?
|
Intraoperative Care | 2 | 2009 | 48 | 0.100 |
Why?
|
Epigenesis, Genetic | 1 | 2012 | 102 | 0.100 |
Why?
|
Survival Rate | 2 | 2011 | 797 | 0.100 |
Why?
|
Transplantation, Autologous | 4 | 2012 | 78 | 0.100 |
Why?
|
Suture Techniques | 1 | 2011 | 56 | 0.100 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2010 | 5 | 0.090 |
Why?
|
Prospective Studies | 4 | 2016 | 2050 | 0.090 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2010 | 26 | 0.090 |
Why?
|
Catheterization | 1 | 2010 | 58 | 0.090 |
Why?
|
Cardiopulmonary Bypass | 1 | 2010 | 57 | 0.090 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2010 | 17 | 0.090 |
Why?
|
Interinstitutional Relations | 1 | 2010 | 11 | 0.090 |
Why?
|
Heart Diseases | 1 | 2011 | 99 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 1080 | 0.090 |
Why?
|
Cell Culture Techniques | 1 | 2010 | 165 | 0.090 |
Why?
|
Venous Pressure | 1 | 2009 | 9 | 0.080 |
Why?
|
Radiography, Interventional | 1 | 2009 | 35 | 0.080 |
Why?
|
Vascular Patency | 1 | 2009 | 68 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 129 | 0.080 |
Why?
|
Probability | 1 | 2009 | 151 | 0.080 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2008 | 11 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 4 | 2017 | 1229 | 0.080 |
Why?
|
Mesenchymal Stem Cells | 1 | 2010 | 166 | 0.080 |
Why?
|
Pipecolic Acids | 1 | 2008 | 6 | 0.080 |
Why?
|
Thrombocytopenia | 1 | 2008 | 32 | 0.080 |
Why?
|
Acute Disease | 2 | 2014 | 239 | 0.080 |
Why?
|
Postoperative Complications | 1 | 2013 | 676 | 0.080 |
Why?
|
Animals | 5 | 2019 | 7341 | 0.080 |
Why?
|
Research Design | 4 | 2010 | 290 | 0.080 |
Why?
|
Heparin | 1 | 2008 | 75 | 0.080 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 533 | 0.070 |
Why?
|
Constriction | 1 | 2006 | 12 | 0.070 |
Why?
|
Algorithms | 1 | 2009 | 468 | 0.070 |
Why?
|
Heart Valve Diseases | 1 | 2006 | 25 | 0.070 |
Why?
|
Myocardial Revascularization | 1 | 2006 | 38 | 0.070 |
Why?
|
Endothelins | 1 | 2005 | 4 | 0.070 |
Why?
|
CD40 Ligand | 1 | 2005 | 13 | 0.070 |
Why?
|
E-Selectin | 1 | 2005 | 20 | 0.070 |
Why?
|
Blood Proteins | 1 | 2005 | 18 | 0.070 |
Why?
|
Serotonin | 1 | 2005 | 35 | 0.070 |
Why?
|
Mitral Valve Insufficiency | 1 | 2006 | 21 | 0.070 |
Why?
|
Mice | 3 | 2019 | 2388 | 0.060 |
Why?
|
Odds Ratio | 2 | 2017 | 448 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2008 | 314 | 0.060 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 294 | 0.060 |
Why?
|
Child, Preschool | 1 | 2007 | 1172 | 0.060 |
Why?
|
Angiopoietin-1 | 1 | 2003 | 6 | 0.060 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2003 | 15 | 0.060 |
Why?
|
Translocation, Genetic | 2 | 2014 | 20 | 0.060 |
Why?
|
Models, Cardiovascular | 1 | 2003 | 27 | 0.060 |
Why?
|
Receptors, CXCR3 | 1 | 2002 | 1 | 0.050 |
Why?
|
Chemokine CXCL9 | 1 | 2002 | 1 | 0.050 |
Why?
|
Chemokine CXCL11 | 1 | 2002 | 1 | 0.050 |
Why?
|
Chemokine CXCL10 | 1 | 2002 | 2 | 0.050 |
Why?
|
Rabbits | 1 | 2003 | 186 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2003 | 107 | 0.050 |
Why?
|
Clinical Trials as Topic | 2 | 2015 | 299 | 0.050 |
Why?
|
Bone Marrow | 2 | 2014 | 61 | 0.050 |
Why?
|
Molecular Sequence Data | 2 | 2014 | 366 | 0.050 |
Why?
|
Transplantation, Homologous | 1 | 2002 | 113 | 0.050 |
Why?
|
Cell Line | 2 | 2014 | 456 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2012 | 139 | 0.050 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 2 | 2012 | 22 | 0.050 |
Why?
|
Cell Survival | 2 | 2012 | 278 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2012 | 18 | 0.050 |
Why?
|
Interdisciplinary Communication | 2 | 2011 | 53 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2002 | 523 | 0.050 |
Why?
|
Chronic Disease | 2 | 2013 | 376 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2013 | 796 | 0.040 |
Why?
|
Spondylolisthesis | 1 | 2019 | 7 | 0.040 |
Why?
|
Spinal Stenosis | 1 | 2019 | 11 | 0.040 |
Why?
|
Scoliosis | 1 | 2019 | 23 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 39 | 0.040 |
Why?
|
Adolescent | 2 | 2019 | 3284 | 0.040 |
Why?
|
Respiratory Distress Syndrome, Adult | 1 | 2019 | 55 | 0.040 |
Why?
|
Rats | 1 | 2003 | 1609 | 0.040 |
Why?
|
Prevalence | 2 | 2013 | 912 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2019 | 249 | 0.040 |
Why?
|
Unnecessary Procedures | 1 | 2017 | 9 | 0.040 |
Why?
|
Pilot Projects | 2 | 2010 | 489 | 0.040 |
Why?
|
Microcirculation | 1 | 2017 | 62 | 0.040 |
Why?
|
Sepsis | 1 | 2019 | 149 | 0.040 |
Why?
|
Organ Size | 1 | 2017 | 196 | 0.040 |
Why?
|
Coronary Thrombosis | 1 | 2017 | 15 | 0.040 |
Why?
|
Heart Ventricles | 1 | 2017 | 108 | 0.040 |
Why?
|
Polymers | 1 | 2017 | 59 | 0.040 |
Why?
|
Receptors, CXCR4 | 1 | 2016 | 11 | 0.040 |
Why?
|
Immunophenotyping | 1 | 2015 | 50 | 0.030 |
Why?
|
Endothelium-Dependent Relaxing Factors | 1 | 2014 | 2 | 0.030 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2014 | 24 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 16 | 0.030 |
Why?
|
Nitric Oxide | 1 | 2014 | 116 | 0.030 |
Why?
|
China | 1 | 2014 | 44 | 0.030 |
Why?
|
Dehydration | 1 | 2013 | 7 | 0.030 |
Why?
|
Quantitative Trait, Heritable | 1 | 2014 | 47 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2014 | 68 | 0.030 |
Why?
|
Models, Genetic | 1 | 2014 | 95 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2014 | 54 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2014 | 148 | 0.030 |
Why?
|
Base Sequence | 1 | 2014 | 255 | 0.030 |
Why?
|
Alleles | 1 | 2014 | 252 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2014 | 109 | 0.030 |
Why?
|
Body Mass Index | 1 | 2016 | 876 | 0.030 |
Why?
|
Transcription Factors | 1 | 2014 | 174 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 643 | 0.030 |
Why?
|
Smoking | 1 | 2016 | 441 | 0.030 |
Why?
|
Lipids | 1 | 2014 | 215 | 0.030 |
Why?
|
Coronary Restenosis | 1 | 2012 | 13 | 0.030 |
Why?
|
Preservation, Biological | 1 | 2012 | 1 | 0.030 |
Why?
|
Consumer Product Safety | 1 | 2012 | 2 | 0.030 |
Why?
|
Angina Pectoris | 1 | 2012 | 19 | 0.030 |
Why?
|
Receptors, Interleukin-7 | 1 | 2012 | 1 | 0.030 |
Why?
|
Genes, Retinoblastoma | 1 | 2012 | 4 | 0.030 |
Why?
|
Aneuploidy | 1 | 2012 | 8 | 0.030 |
Why?
|
Retinoblastoma Protein | 1 | 2012 | 11 | 0.030 |
Why?
|
Janus Kinases | 1 | 2012 | 5 | 0.030 |
Why?
|
Transportation | 1 | 2012 | 14 | 0.030 |
Why?
|
Genotype | 1 | 2014 | 735 | 0.030 |
Why?
|
Chromosomal Instability | 1 | 2012 | 3 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2012 | 13 | 0.030 |
Why?
|
Automation | 1 | 2012 | 30 | 0.030 |
Why?
|
Genes, ras | 1 | 2012 | 27 | 0.030 |
Why?
|
Injections | 1 | 2012 | 61 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 37 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 494 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2012 | 34 | 0.030 |
Why?
|
Cell Death | 1 | 2012 | 74 | 0.030 |
Why?
|
Anticoagulants | 1 | 2013 | 122 | 0.030 |
Why?
|
Histones | 1 | 2012 | 49 | 0.030 |
Why?
|
Age of Onset | 1 | 2012 | 96 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2012 | 72 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2012 | 114 | 0.020 |
Why?
|
Cryopreservation | 1 | 2012 | 54 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2012 | 62 | 0.020 |
Why?
|
Phlebography | 1 | 2011 | 26 | 0.020 |
Why?
|
Oxygen Consumption | 1 | 2012 | 139 | 0.020 |
Why?
|
Genome, Human | 1 | 2012 | 129 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2012 | 116 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2011 | 105 | 0.020 |
Why?
|
Graft Survival | 1 | 2012 | 228 | 0.020 |
Why?
|
Automation, Laboratory | 1 | 2010 | 3 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2010 | 8 | 0.020 |
Why?
|
Injections, Intralesional | 1 | 2010 | 13 | 0.020 |
Why?
|
Cell Count | 1 | 2010 | 51 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2011 | 51 | 0.020 |
Why?
|
Prognosis | 1 | 2014 | 1373 | 0.020 |
Why?
|
Quality Control | 1 | 2010 | 38 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 252 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2010 | 23 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2010 | 173 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 14 | 0.020 |
Why?
|
Placebo Effect | 1 | 2010 | 14 | 0.020 |
Why?
|
Patient Care Team | 1 | 2011 | 124 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2012 | 173 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 93 | 0.020 |
Why?
|
Ventricular Remodeling | 1 | 2010 | 53 | 0.020 |
Why?
|
Program Development | 1 | 2010 | 85 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2010 | 73 | 0.020 |
Why?
|
Hypertension | 1 | 2016 | 918 | 0.020 |
Why?
|
Linear Models | 1 | 2010 | 427 | 0.020 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2009 | 4 | 0.020 |
Why?
|
Pulmonary Veins | 1 | 2009 | 9 | 0.020 |
Why?
|
Obesity | 1 | 2016 | 1082 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 2009 | 23 | 0.020 |
Why?
|
Ultrasonography | 1 | 2011 | 350 | 0.020 |
Why?
|
Diastole | 1 | 2009 | 91 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2009 | 270 | 0.020 |
Why?
|
Platelet Count | 1 | 2008 | 21 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 2014 | 588 | 0.020 |
Why?
|
Sternum | 1 | 2006 | 13 | 0.020 |
Why?
|
Angiography | 1 | 2006 | 75 | 0.020 |
Why?
|
Child | 1 | 2012 | 2234 | 0.020 |
Why?
|